Detrol Sales Potential Could Be $1 Bil. With Once-Daily Indication, P&U Says
Executive Summary
The sales potential of Pharmacia & Upjohn's overactive bladder treatment Detrol (tolterodine) could be up to half a billion dollars greater than previous projections, pending approval of a once-daily formulation.
You may also be interested in...
Pharmacia Detrol LA Once-Daily Formulation To Be Promoted By 2,000 Reps
Pharmacia will use 2,000 sales reps to promote Detrol LA, the company said following the Dec. 22 approval of the once-daily formulation of its overactive bladder drug tolterodine.
Pharmacia Detrol LA Once-Daily Formulation To Be Promoted By 2,000 Reps
Pharmacia will use 2,000 sales reps to promote Detrol LA, the company said following the Dec. 22 approval of the once-daily formulation of its overactive bladder drug tolterodine.
Vestra
P&U receives second "approvable" letter for the reboxetine antidepressant Feb. 23. P&U said it conducted two U.S. trials for Vestra to supplement the non-U.S. data in its NDA following the first "approvable" letter in July, but only one showed efficacy on the primary endpoint (1"The Pink Sheet" Feb. 14, p. 29)